US-headquartered genomic drug developer Denovo Biopharma has completed a series D round featuring a fund operated by pharmaceutical producer CR Pharma, at almost RMB300m ($45.8m), DealStreetAsia reported yesterday.
CICC Capital’s CICC Qide fund co-led the round with Yingke PE, according to a WeChat post cited by DealStreetAsia. It included Silicon Paradise Asset Management Group, Fang Fund Partners, Sangel Capital, Hosencare Brothers and Zheshang Industrial Integration Asset Management.
Denovo is developing gene therapies for cancer and central nervous system disorders, and will put the funding into advancing its product pipeline.
The company raised $83.4m in a June 2020 series C round led by CICC Capital that included Yingke PE, Share Capital, Citic Securities Investment, Sangel Capital, Jiuyo Capital, Shenzhen Guozhong Venture Capital Management and Kaitou Hanrun Investment.
Jiuyou Capital, Sangel Capital, Share Capital, Zheshang Industrial Integration, Yuexiu Industrial Fund, Qianzhan Capital and Wenfang Technology had provided $42.5m in series B funding for Denovo in October 2019, following an undisclosed amount in a 2015 series A round.